Authors

Latest:

Dr. Zevallos on Molecular Profile of HPV-Positive Oropharyngeal SCC Stratified by Smoking Status

Jose P. Zevallos, MD, MPH, FACS, assistant professor, director of Oncologic Research, University of North Carolina School of Medicine, discusses a study that examined the molecular profile of patients with HPV-positive oropharyngeal squamous cell carcinoma (SCC) stratified by smoking status.

Josep M. Llovet, MD, PhD, Mount Sinai School of Medicine

Latest:

Future Directions for HCC Management

Drs Josep Llovet, Stephen L. Chan, and Andrea Casadei Gardini discuss the future treatment landscape for HCC.

Josep Llovet, MD, PhD, Icahn School of Medicine at Mount Sinai

Josep M. Llovet, MD, PhD

Latest:

Dr Llovet on the Efficacy of TACE With or Without Lenvatinib Plus Pembrolizumab in HCC

Josep Llovet, MD, discusses the effiacy of TACE treatment with or without lenvatinib plus pembrolizumab in intermediate-stage hepatocellular carcinoma.

Josep Tabernero, MD, PhD

Latest:

Dr. Tabernero on the Efficacy of Bevacizumab Plus TAS-102 in Refractory mCRC

Josep Tabernero, MD, PhD, discusses findings from the phase 3 SUNLIGHT trial investigating the combination of bevacizumab plus trifluridine/tipiracil vs TAS-102 alone in patients with refractory metastatic colorectal cancer.

Joseph A. Califano, MD

Latest:

Dr. Califano Discusses the Role of Surgery in Head and Neck Cancer

Joseph A. Califano, MD, professor of surgery, University of California, San Diego, discusses the role of surgery in head and neck cancer.

Joseph A. Sparano, MD

Latest:

Dr. Sparano on the Utility of Liquid Biopsies in Breast Cancer

Joseph A. Sparano, MD, associate director for clinical research, Albert Einstein Cancer Center, professor of Medicine & Obstetrics, Gynecology, and Women’s Health at the Albert Einstein College of Medicine, and associate chairman for Clinical Research in the Department of Oncology at Montefiore Medical Center, discusses the utility of liquid biopsies in breast cancer.

Joseph A. Sparano, MD, Albert Einstein College of Medicine

Joseph Alvarnas, MD

Latest:

Dr. Alvarnas on the Importance of Access to CAR T-cell Therapy in Cancer Care

Joseph Alvarnas, MD, discusses the importance of access to CAR T-cell therapy in cancer care.

Joseph Antin, MD, Dana-Farber Cancer Institute

Joseph Burns

Latest:

Practices in Bundled Payment Program Credit Medical Home Structure for Success

In July, UnitedHealthcare (UHC) reported that an innovative program using bundled payment for cancer care resulted in an impressive 34% reduction in medical costs when compared with costs for a control group

Joseph Chao, MD

Latest:

Dr. Chao on the Utility of MSI as a Biomarker in Gastric/GEJ Cancer

Joseph Chao, MD, discusses the utility of microsatellite instability (MSI) status as a prognostic biomarker in gastric and gastroesophageal cancer.

Joseph Ciccolini, PhD

Latest:

Dr. Ciccolini on Dose Levels of Cetuximab in Head and Neck Cancer

Joseph Ciccolini, PhD, assistant professor in Pharmocokinetics, Aix-Marseille University, discusses dose levels of cetuximab (Erbitux) in patients with head and neck cancer.

Joseph F. Renzulli, II, MD, FACS

Latest:

Dr. Renzulli on Expanded Access Program With Radium-223

Joseph F. Renzulli, II, MD, FACS, assistant professor of surgery (urology) clinical, Alpert Medical School, discusses the expanded access program in the United States for radium-223 dichloride in patients with metastatic castration-resistant prostate cancer.

Joseph G. Jurcic, MD

Latest:

Dr Jurcic on the Evolution of Combination Therapies in the Management of Myelofibrosis

Joseph G. Jurcic, MD, discusses the evolution of combination therapies in the management of myelofibrosis.

Joseph H. Antin, MD, Dana-Farber Cancer Institute

Latest:

Updates in the Management of Graft-Versus-Host Disease

Joseph Jurcic, MD

Latest:

Dr. Jurcic on Lintuzumab and Low-Dose Cytarabine for AML

Joseph Jurcic, MD, professor of Clinical Medicine, director of the Hematologic Malignancies Section of the Hematology/Oncology Division, Columbia University Medical Center, discusses a phase I trial of lintuzumab and low-dose cytarabine (LDAC) in older patients with untreated acute myeloid leukemia (AML).

Joseph Leach, MD

Latest:

Dr. Leach on Brigatinib in ALK-Positive NSCLC

Joseph Leach, MD, medical oncologist at Minnesota Oncology, discusses the use of brigatinib (Alunbrig) in ALK-positive non–small cell lung cancer (NSCLC).

Joseph M. Flynn, DO

Latest:

Dr. Flynn on Obinutuzumab for the Treatment of CLL

Joseph M. Flynn, DO, MPH, discusses the results of the phase II GAGE study, which compared 1000 mg vs 2000 mg of obinutuzumab in patients with chronic lymphocytic leukemia (CLL).

Joseph M. Unger, MS, PhC

Latest:

Joseph Unger on Low-Income Clinical Trial Participation

Joseph Unger, from the SWOG Statistical Center at the Fred Hutchinson Cancer Research Center, on Low-Income Clinical Trial Participation.